c-FMS (CSF1R, CSF-1R) is a receptor protein-tyrosine kinase of the platelet-derived growth factor receptor (PDGFR) family. The cell surface receptor for IL-34 and CSF1 is called c-FMS. Important functions of c-FMS include regulating haematopoiesis, cell survival, maturation of microglia and monocytes, and immune response regulation.
Osteoclasts and myelomonocytic-lineage cells, like monocytes and macrophages, express c-FMS specifically, and the activation of c-FMS signaling encourages the proliferation or differentiation of these cells. Additionally, it encourages the production of inflammatory mediators like interleukin 6 (IL6) and tumor necrosis factor-alpha (TNF-).
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V69281 | Anumigilimab (CSL-324) | 2416593-08-1 | Anumigilimab (CSL-324) is a humanized IgG2a monoclonal antibody (mAb) targeting the human granulocyte colony-stimulating factor (G-CSF) receptor. |
|
V69279 | Axatilimab (SNDX-6352) | 2155851-88-8 | Axatilimab (SNDX-6352) is a human IgG4 antibody with high affinity for CSF-1R. |
|
V4238 | AZD7507 | 1041852-85-0 | AZD7507 is a novel, potent, selective and orally bioactive 3-amido-4-anilinoquinoline CSF-1R inhibitor with 32 nM cell activity and with antitumor activity. |
|
V69288 | BPR1R024 mesylate | 2763365-40-6 | BPR1R024 mesylate is a selective, orally bioactive, colony-stimulating factor-1 receptor (CSF1R) inhibitor. |
|
V69274 | c-Fms-IN-13 | 885704-58-5 | c-Fms-IN-13 (compound 14) is a potent FMS kinase inhibitor (antagonist) with IC50 of 17 nM. |
|
V69272 | c-Fms-IN-14 | 1898210-99-5 | c-Fms-IN-14 (Example 76) is a c-Fms inhibitor (antagonist) with IC50 of 4 nM. |
|
V69275 | Cabiralizumab (FPA 008; Anti-Human CSF1R Recombinant Antibody) | 1613144-80-1 | Cabiralizumab (FPA 008) is an anti-CSF1R monoclonal antibody (mAb). |
|
V4438 | cFMS Receptor Inhibitor II | 959860-85-6 | cFMS Receptor Inhibitor II (BUN60856; BUN-60856) is a novel, cell-permeable and potent CSF1R (Colony stimulating factor 1 receptor) kinase inhibitor with an IC50 of 80 nM. |
|
V69284 | cFMS Receptor Inhibitor IV | 959626-45-0 | cFMS receptor blocker/inhibitor IV (Compound 42) is a potent inhibitor of cFMS with IC50 of 0.017 μM. |
|
V31740 | CSF1R-IN-1 | 2095849-04-8 | CSF1R-IN-1 is an inhibitor (blocker/antagonist) of CSF1R with IC50 of 0.5 nM. |
|
V69287 | CSF1R-IN-15 | 2925744-43-8 | CSF1R-IN-15 (compound 23) is an inhibitor (blocker/antagonist) of c-Fms. |
|
V79871 | CSF1R-IN-17 | CSF1R-IN-17 (compound 9) is a potent and specific CSF1R antagonist (inhibitor) with IC50 of 0.2 nM. | |
|
V3765 | Edicotinib | 1142363-52-7 | Edicotinib (formerly known as JNJ-527; JNJ-40346527) is a novel selective and orally bioavailable inhibitor of colony-stimulating factor-1 (CSF-1) receptor kinase with anticancer activity. |
|
V69277 | Eflapegrastim | 1384099-30-2 | Eflapegrastim is a humanized IgG4 monoclonal antibody (mAb) and a granulocyte colony-stimulating factor (G-CSF). |
|
V69273 | Emactuzumab (RG 7155; RO 5509554) | 1448221-67-7 | Emactuzumab (RG 7155) is a specific monoclonal antibody (mAb) that can inhibit activation of the colony-stimulating factor 1 receptor (CSF1R). |
|
V69289 | IACS-9439 | 2231259-36-0 | IACS-9439 is a specific, orally bioactive CSF1R inhibitor (antagonist) with a Ki of 1 nM. |
|
V23228 | KI-20227 | 623142-96-1 | KI-20227 is a potent and orally bioavailable inhibitor of c-Fms tyrosine kinase (M-CSFR, CSF1R) (IC50 are 2, 12, 217 and 451 nM for c-Fms, VEGFR-2, PDGFRβ and c-Kit respectively). |
|
V69276 | Lacnotuzumab (MCS110; Anti-Human B7-H3) | 1831128-32-5 | Lacnotuzumab (MCS110) is a neutralizing humanized IgG1/κ monoclonal antibody (mAb) that targets CSF-1 and prevents CSF-1 from activating the CSF-1R. |
|
V69278 | Namilumab (AMG-203; Anti-Human CSF2 Recombinant Antibody) | 1206681-39-1 | Namilumab (AMG203) is a human IgG4 monoclonal antibody (mAb) that binds to GM-CSF ligand with high affinity and effectively neutralizes GM-CSF. |
|
V69286 | Otilimab (GSK 3196165; MOR103) | 1638332-55-4 | Otilimab (GSK 3196165) is an anti-granulocyte-macrophage colony-stimulating factor (GM-CSF) humanized monoclonal antibody (mAb). |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
